Table 2.

Quality indicators for treatment and management of Barrett’s esophagus and early cancer using a modified Delphi method from Sharma etal. [22••]

	Quality indicator	Agreement	Grade of recommendation
Screening, diagnosis, and staging	For patients in whom BE is being considered, the squamocolumnar junction, the gastroesophageal junction (GEJ), and the location of the diaphragmatic hiatus (if there is a hiatal hernia present) should be recorded on each upper endoscopy	87% [35% strongly agree, 52% agree]	Weak
	If BE is suspected on an endoscopy, the endoscopist should document the extent of suspected BE using Prague criteria	82.6% [43.5% strongly agree, 39.1% agree]	Weak
	The normal-appearing and normally located squamocolumnar junction should not be biopsied	86.3% [68.1% strongly agree, 18.2% agree]	Strong
Surveillance	If systematic surveillance biopsies performed in a patient known to have BE show no evidence of dysplasia, follow-up surveillance endoscopy should be recommended no sooner than 3 to 5 years	91.3% [17.3% strongly agree, 74% agree]	Weak
	If a patient with known BE undergoes surveillance endoscopy, systematic biopsies should be taken from every 1 to 2 cm in 4 quadrants throughout the extent of the endoscopically involved segment.	95.7% [52.2% strongly agree, 43.5% agree]	Strong
	If a patient with known BE undergoes surveillance endoscopy, biopsies from any visible raised or depressed lesions should be obtained and processed separately from the systematic biopsies	95.7% [65.2% strongly agree, 30.5% agree]	Strong
Treatment and management	In patients with dysplastic BE or early EAC, a diagnostic endoscopic resection should be performed on any raised or suspicious areas	95.6% [65.2% strongly agree, 30.5% agree]	Strong
	In patients with BE-associated neoplasia, the goal of endoscopic treatment should be complete eradication of the BE segment in addition to any dysplastic lesions	100% [65.2% strongly agree, 34.8% agree]	Strong

BE Barrett’s esophagus